Geron announces first patient dosed in expanded part 1 of IMerge clinical trial in MDS
Geron announced the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes who are refractory or resistant to treatment with an ESA. November 20, 2017